Aehr Test: Nine Insiders Sell $17M at 52-Week High
Nine Aehr Test Systems insiders sold $17.30 million in open-market shares between August 4 and August 17, 2026, all at or near the stock's 52-week high, with zero purchases recorded on the other side.
Aehr Test CEO Sells $5M Into Stock's 52-Week High
NEW YORK, August 24 —
Aehr Test Systems, Inc. (AEHR) reported record quarterly bookings and a $100 million effective backlog in Q4 FY2026, then nine insiders including CEO Gayn Erickson sold $17.30 million in stock between August 4 and August 17, 2026, all at or near the stock's 52-week high. The backlog narrative is intact; what the selling pattern suggests is the harder question.
- Q4 FY2026 EPS of $0.11 beat the − consensus by 1,600%; record bookings and a $100M effective backlog.
- Nine insiders sold $17.30M in open-market shares between August 4 and August 17, 2026, with zero purchases recorded.
- Forward P/E: 73.5x on negative trailing EPS; trailing revenue approximately $50M growing 33.7% year over year; negative operating cash flow.
Nine Sellers, Zero Buyers
The breadth sets this apart from routine executive diversification. Aehr Test Systems makes FOX-XP and FOX-NP systems that test, burn-in, and stabilize silicon carbide and gallium nitride power semiconductors, memory chips, and photonics devices for AI applications. CEO Gayn Erickson sold $5.23 million on August 12, the same day COO Adil Engineer netted $1.97 million and Director Geoffrey Gates Scott sold $2.63 million while also gifting 6,731 shares. Director Howard Slayen had opened the window on August 4 with a $2.17 million sale and returned August 14 for $758,000 more. Nine insiders, thirteen days, $17.30 million, zero purchases.
What 73.5x Buys in This Business
At 73.5x forward earnings on a stock with negative trailing EPS and negative operating cash flow of $3 million, the $100 million effective backlog has already been priced in, and then some. Aehr's $3.32 billion market capitalization against roughly $50 million in trailing revenue demands years of high-margin execution, the kind of scenario a DCF calculator stress-tests quickly. The S-3ASR shelf registration filed July 27, thirteen days after the Q4 earnings release, allows Aehr to issue shares with minimal lead time, adding a dilution overhang to a stock where perfect execution is already the price of admission.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| AEHR | $3.3B | 73.5x | +313.7% |
| AXTI | $4.6B | 31.8x | +2390.8% |
| AAOI | $10.6B | 27.1x | +412.8% |
| CRDO | $43.0B | 25.3x | +99.8% |
| NVTS | $3.4B | n/a | +109.2% |
| ACLS | $3.9B | 24.1x | +58.1% |
The Number That Would Prove It Wrong
The bull case exists: analysts carry a $130 consensus price target above current levels, and 13.9% short interest means any positive catalyst can generate violent covering. The setup tilts bearish, though, as long as insiders collectively reduce exposure at the annual high with no recorded purchase on the other side, that multiple demanding perfection, and a live dilution shelf. The number that changes this is backlog conversion: if Q1 FY2027 revenue materially clears the trailing run-rate and operating cash flow turns positive, the August selling looks like routine planning. Until then, run the free Aehr Test Systems, Inc. deep-dive → and track whether the numbers follow the narrative.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
Why did Aehr Test Systems insiders sell $17M in stock?
Nine insiders including CEO Gayn Erickson sold $17.30 million in open-market shares between August 4 and August 17, 2026, all at or near the stock's 52-week high. Zero purchases were recorded across the same thirteen-day window. The article identifies the breadth of nine individual sellers as what distinguishes this from routine executive diversification.
What is Aehr Test Systems' forward P/E ratio?
Aehr Test Systems carries a 73.5x forward P/E against negative trailing earnings per share. The company also reported negative operating cash flow of $3 million. At that multiple, the $100 million effective backlog has already been priced in, demanding years of high-margin execution.
What products does Aehr Test Systems make?
Aehr Test Systems makes FOX-XP and FOX-NP systems that test, burn-in, and stabilize silicon carbide and gallium nitride power semiconductors, memory chips, and photonics devices for AI applications.
What is Aehr Test Systems' short interest?
Short interest in Aehr Test Systems stands at 13.9%. Any positive catalyst could generate violent covering, which anchors the bull case alongside a $130 analyst consensus price target above current levels.
What is the Aehr Test Systems S-3ASR shelf registration?
Aehr Test Systems filed an S-3ASR shelf registration on July 27, thirteen days after the Q4 FY2026 earnings release. The filing allows the company to issue new shares with minimal lead time, adding a dilution overhang to a stock where perfect execution is already the price of admission.
Aehr Test Systems shares hit a 52-week high last week, fueled by record quarterly bookings and a $100 million effective backlog — yet in the same two-week window, nine insiders including CEO Gayn Erickson sold more than $17 million in open-market stock at those very peaks. The divergence forces investors to reconcile an executive team publicly touring the backlog story at investor conferences with one that collectively liquidated $17 million of equity at the stock's annual high.